Press Releases

GWOXI Stem Cell participated in the INTERPHEX Week Tokyo: Pharmaceutical & Regenerative Medicine Exhibition to launch a series of strategic collaborations and exchanges in the regenerative medicine industry, aiming to advance international licensing and product commercialization partnerships.

With Taiwan now a super-aged society and the persistent trend of younger-onset stroke, GWOXI Stem Cell's new stem cell drug for stroke, GXNPC1, has been submitted for a Phase III clinical trial and is poised for an accelerated launch with an early-to-market drug license.

GWOXI Stem Cell announced that the Phase III clinical trial for its allogeneic adipose stem cell drug, GXCPC1, for the treatment of osteoarthritis, has been approved by Taiwan's Ministry of Health and Welfare (MOHW). This makes it one of the few stem cell drugs in Taiwan to successfully advance to this late-stage clinical trial.

Following the legislative passage of the Regenerative Medicine Act and Regulations, GWOXI will target potential business opportunities by building its patent portfolio and advancing the clinical validation of its new cell drugs, while also strengthening its cell manufacturing capabilities and actively obtaining PIC/S GMP certification.

Leveraging its robust patent portfolio and supply chain integration capabilities, GWOXI Stem Cell has successfully advanced multiple innovative technologies from clinical translation to commercialization, providing patients with novel treatment options.

Application for Review of the Phase III Human Clinical Trial for the Adipose Stem Cell Drug, Ruanshili (GXCPC1), for the Treatment of Osteoarthritis.

Developed by GWOXI Stem Cell, the new diabetes drug Yidaosu (GXIPC1®) has obtained patents in the United States, China, and Taiwan, which will help accelerate its commercialization timeline.

GWOXI Stem Cell, which has two stem cell therapy products in Phase III clinical trials, is racing to obtain PIC/S GMP certification by the end of October to prepare for future drug approvals and its global expansion strategy.

GWOXI Stem Cell has established a pet regenerative medicine network by partnering with multiple veterinary clinics, veterinary associations, and distributors, and is continuing to expand its market presence.

GWOXI Stem Cell Corp. announced the preliminary results of its joint Phase I human clinical trial for diabetes in collaboration with Vietnam. The results showed good safety and tolerability. The company will subsequently submit the findings to Vietnam's Ministry of Health for official filing and review.